TrialInternational urogynecology journal2013
A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Christopher R Chapple et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
50 papers cite it
this paperpooled ittrialcites it